The Rx Price Watch report from the Public Policy Institute of the American Association of Retired Persons (AARP) has found that retail prices of widely used brand name prescription drugs rose at a significantly faster rate than general inflation over the past decade.
The Rx Price Watch report developed by Leigh Purvis, MPA, of the American Association of Retired Persons (AARP) and Stephen W. Schondelmeyer, PharmD, PhD, PRIME Institute, University of Minnesota, has found that retail prices of widely used brand name prescription drugs rose at a significantly faster rate than general inflation over the past decade. Specifically, in 2015, the retail prices for 268 drugs in this category saw an average price increase of 15.5%, while the general inflation rate was 0.1% during the same time period.
The report, “Trends in Retail Prices of Brand Name Prescription Drugs Widely Used by Older Americans, 2006 to 2015,” examined the price trends for the most commonly used branded prescription drugs in 2015. Additionally, the authors calculated the 10-year cumulative retail price changes for popular branded prescription drugs for the period between 2006 and 2015, and retail price changes for these drugs based on their therapeutic category and the manufacturer. The following are some of the report’s findings:
The authors wrote that an increase in the price of branded drugs always translates into an increase in out-of-pocket costs—particularly for consumers who have a coinsurance instead of copayment. Additionally, insurance companies compensate for the price increase by raising deductibles and premiums for enrollees. Overall, prescription drug price increases also impact taxpayer-funded programs like Medicare and Medicaid.
The report advices health policy experts to take note of this recent trend in pharmaceutical drug prices and focus their attention on ways to balance innovation with consumer health, and financial security.
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen